Intranasal Epinephrine Spray Shows Superior Pharmacokinetics to Autoinjector in Anaphylaxis Treatment Study
核心洞察
A 13.2 mg intranasal epinephrine spray demonstrated higher maximum plasma concentrations and greater systemic exposure compared to the standard 0.3 mg autoinjector in a crossover study of 116 healthy adults.
The intranasal delivery achieved therapeutic epinephrine levels for twice as long as the autoinjector while maintaining comparable safety profiles and cardiovascular effects.
The needle-free spray addresses critical unmet needs in anaphylaxis (搜索) treatment, potentially reducing administration delays caused by needle anxiety and improving patient compliance with carrying emergency epinephrine.
A novel intranasal epinephrine spray has demonstrated superior pharmacokinetic properties compared to standard autoinjectors in treating anaphylaxis (搜索), potentially addressing longstanding barriers to emergency epinephrine administration. The findings from a comprehensive crossover study suggest the needle-free delivery system could significantly improve patient outcomes in life-threatening allergic reactions.
Enhanced Drug Exposure Profile
The open-label, three-period crossover study involving 116 healthy adult volunteers compared a 13.2 mg intranasal epinephrine dose with both 0.3 mg autoinjector and 0.5 mg manual syringe intramuscular injections. The intranasal formulation achieved a maximum observed concentration of 429.4 pg/mL compared to 328.6 pg/mL for the autoinjector, representing a 31% increase in peak plasma levels.
More significantly, the intranasal spray demonstrated greater systemic exposure with an AUC0-360 of 39,060 pg•min/mL versus 17,440 pg•min/mL for the autoinjector—more than doubling the total drug exposure over six hours. This enhanced exposure profile translated to therapeutic epinephrine levels (≥100 pg/mL) being maintained for twice as long compared to the autoinjector.
"The ability to get higher plasma concentrations via intranasal delivery has the potential to circumvent some of the challenges observed with the use of autoinjectors, as well as the need for a second dose, especially in an outpatient setting," the researchers noted.
Addressing Critical Treatment Gaps
The study addresses significant unmet needs in anaphylaxis (搜索) management, where current treatment relies exclusively on needle-based devices. Only 30% to 40% of individuals experiencing anaphylaxis receive epinephrine through autoinjectors, largely due to reluctance to use self-injectors, needle anxiety, and application errors.
The incidence of anaphylaxis (搜索) ranges between 50 and 112 episodes per 100,000 person-years, with lifetime prevalence estimated at 0.3% to 5.1%. Notably, the rate is increasing approximately 3% to 5% per year, particularly in young people. Among food-allergic adults, 51.1% have experienced severe reactions, yet only 24.0% report having a current epinephrine prescription.
Comparable Safety and Tolerability
The intranasal spray demonstrated a safety profile consistent with established epinephrine products. No serious or unexpected adverse events were reported across either study cohort. The cardiovascular effects—including changes in blood pressure and heart rate—were similar between intranasal and autoinjector administration.
In cohort 1, mean heart rate changes ranged from -11.2 to +8.7 beats per minute for intranasal administration compared to -5.7 to +7.4 beats per minute for the autoinjector. Blood pressure changes were minimal across all treatments, with no changes exceeding 20 mm Hg for systolic pressure or 10 mm Hg for diastolic pressure.
Clinical Implications for Emergency Treatment
The enhanced pharmacokinetic profile could prove particularly valuable given that identification of anaphylaxis (搜索) is often delayed or missed in up to 50% of patients, even in healthcare settings. The study found that 67% of subjects receiving intranasal epinephrine achieved plasma levels equivalent to those seen with autoinjector treatment within approximately 6-8 minutes.
The bidose delivery system (two consecutive 6.6 mg sprays) showed consistent performance whether administered to opposite nostrils or the same nostril, though opposite-nostril administration yielded 9% to 30% higher exposures. The time to maximum concentration was 20 minutes for intranasal delivery, bracketed between the autoinjector's 14.9 minutes and manual syringe's 45 minutes.
Pediatric Considerations
While conducted in healthy adults, the findings have important implications for pediatric patients, who face particular challenges with autoinjector use. Anaphylaxis (搜索) incidence in children may reach 761 per 100,000 person-years, with peak occurrence around age 12. Dose-proportionality analysis suggests a single 6.6 mg intranasal spray demonstrates superior pharmacokinetics compared to the 0.15 mg pediatric autoinjector dose.
Future Treatment Paradigm
The research supports intranasal epinephrine as a viable first-line alternative to intramuscular autoinjectors, potentially eliminating barriers associated with needle-based delivery systems. By providing higher and more sustained therapeutic plasma levels while maintaining comparable safety, the intranasal spray could improve patient compliance, reduce administration delays, and optimize clinical outcomes in anaphylaxis (搜索) management.
The study's findings represent a significant advancement in addressing the acknowledged suboptimal use of emergency epinephrine, offering healthcare providers and patients a needle-free option that may enhance preparedness and response in life-threatening allergic reactions.